Inventiva Narrows H1 2026 Loss; Lanifibranor MASH Data Due This Quarter

Inventiva (IVA) reported a narrower net loss for the first half of 2026, improving on the prior-year period as the clinical-stage biopharmaceutical company advances its lead drug candidate. The France-based company is developing lanifibranor for metabolic dysfunction-associated steatohepatitis (MASH). A key data readout from a clinical trial is expected before the end of the current quarter. Inventiva did not disclose specific financial figures in the announcement. Lanifibranor is an oral pan-PPAR agonist positioned in the competitive MASH treatment landscape, where several rivals have recently reported late-stage results.